Can I Take Calcium with Leqvio (Inclisiran)?

How Inclisiran Works and Why Route of Administration Matters

Inclisiran (Leqvio) is a small interfering RNA (siRNA) that silences PCSK9 gene expression in hepatocytes. A clinician injects it subcutaneously into the abdomen, upper arm, or thigh. From there it travels through the lymphatics into systemic circulation, reaches the liver via GalNAc-ligand targeting, and reduces production of the PCSK9 protein, which normally degrades LDL receptors on the hepatocyte surface. The FDA approved inclisiran in December 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or established ASCVD who need additional LDL-C lowering. [1]

Why Oral Absorption Matters for Supplement Interactions

Most drug-supplement interactions involving calcium happen in the gastrointestinal tract. Calcium ions form insoluble chelates with tetracyclines, fluoroquinolones, thyroid hormone (levothyroxine), and bisphosphonates, cutting their absorption by 20 to 80%. This chelation mechanism is well characterized in pharmacokinetic literature and forms the basis of standard "separate by two hours" counseling for those medications. [2]

Inclisiran never enters the GI lumen. It is manufactured as a sodium salt solution and injected. There is no oral bioavailability to speak of, no pill to dissolve, and no intestinal absorption step to disrupt. Calcium in the gut simply has nothing to chelate.

Subcutaneous Injection Pharmacokinetics

After subcutaneous injection, inclisiran reaches peak plasma concentration (Cmax) in approximately 4 hours. Plasma half-life is roughly 9 hours, but the intrahepatic pharmacodynamic effect persists for 6 months because the drug integrates into the RNA-induced silencing complex (RISC) inside hepatocytes. Pharmacokinetic data from the ORION-1 trial showed that inclisiran's hepatic dwell time, not plasma exposure, drives its duration of action. [3] Calcium has no mechanism to influence either the hepatic uptake via GalNAc receptors or the RISC complex.

The Calcium-Cardiovascular Risk Debate

Observational Data Linking Calcium Supplements to CV Events

Some observational studies have raised concern that high-dose supplemental calcium may increase cardiovascular risk. A re-analysis of the Women's Health Initiative (WHI) trial (N=36,282) reported a modest increase in myocardial infarction risk among women randomized to calcium plus vitamin D versus placebo (hazard ratio 1.13, 95% CI 1.01 to 1.25 in a subset with no prior personal supplement use). That finding, published in the BMJ, prompted significant debate about whether supplemental calcium accelerates vascular calcification. [4]

Inclisiran is prescribed specifically to patients who already carry elevated cardiovascular risk. Patients with HeFH or established ASCVD are exactly the population in whom any additional CV risk from calcium supplementation would be most consequential.

What the Data Actually Show

The connection between calcium supplements and vascular events is not settled. A 2020 meta-analysis published in the Journal of the American Heart Association examined 13 randomized controlled trials and found no statistically significant association between calcium supplementation and major adverse cardiovascular events (MACE) when trials with active co-interventions were excluded. That analysis also noted substantial heterogeneity across studies, making a firm causal conclusion premature. [5]

Dietary calcium, by contrast, has not shown the same signal. The current evidence suggests that food-based calcium intake at recommended levels (1,000 to 1,200 mg/day for most adults) does not carry the same theoretical risk as bolus supplemental doses. The NIH Office of Dietary Supplements sets the Tolerable Upper Intake Level (UL) for calcium at 2,500 mg/day for adults aged 19 to 50 and 2,000 mg/day for those over 50. [6]

Clinical Takeaway for Patients on Inclisiran

Patients on inclisiran are high-risk cardiovascular patients by definition. If calcium supplementation is needed for bone health, keeping total intake (diet plus supplements) at or below 1,200 mg/day and preferring dietary sources over large bolus supplements is the most defensible clinical position given current data. The decision belongs to the prescribing clinician, not to self-guided supplementation.

Pharmacokinetic Profile: Inclisiran in Detail

Absorption, Distribution, Metabolism, Excretion

Inclisiran is absorbed rapidly from the subcutaneous injection site, with an absolute bioavailability near 100% via the SC route. It distributes primarily to the liver due to GalNAc targeting. Metabolism occurs via nuclease-mediated cleavage, the same enzymatic machinery that degrades endogenous RNA. Renal excretion of intact and metabolite fragments accounts for the primary elimination pathway. The prescribing information specifies no dose adjustment for mild-to-moderate hepatic impairment, though data in severe hepatic impairment are limited. [1]

None of these steps involve cytochrome P450 enzymes, P-glycoprotein, or other transporters that calcium could plausibly modulate. CYP-mediated interactions account for a large fraction of all clinically significant drug-drug interactions; inclisiran sidesteps that entire system.

Drug Interaction Profile from Clinical Trials

The ORION clinical trial program enrolled thousands of patients, many taking multiple cardiovascular and metabolic medications. ORION-10 (N=1,561) enrolled patients with established ASCVD already on maximally tolerated statins and reported a 52.3% placebo-corrected LDL-C reduction at 510 days with no interaction signals emerging from concomitant medications including antihypertensives, antidiabetics, and common supplements. [7]

ORION-9 (N=482) focused on heterozygous familial hypercholesterolemia patients and showed a 49.3% LDL-C reduction from baseline at day 510, again without drug-interaction-driven safety signals in the trial population. [8] Neither trial specifically excluded patients on calcium supplements, and no calcium-related adverse events were flagged in the published safety summaries.

Calcium's Known Interactions with Other Medications Commonly Prescribed Alongside Leqvio

Inclisiran rarely travels alone in a patient's medication list. Patients with HeFH or ASCVD typically take statins, ezetimibe, antihypertensives, and sometimes levothyroxine or bisphosphonates for bone health. Calcium does interact with several of these agents, and that is where clinician attention belongs.

Levothyroxine

Calcium carbonate and calcium citrate both reduce levothyroxine absorption significantly when taken together. A controlled study showed that calcium carbonate 1,200 mg reduced levothyroxine absorption, raising TSH by a mean of 2.7 mIU/L over 3 months in hypothyroid patients who were previously stable. That trial, published in the New England Journal of Medicine, is the standard evidentiary basis for separating levothyroxine from calcium by at least four hours. [9] Patients on Leqvio who also take levothyroxine should be counseled on this separation, even though inclisiran itself is unaffected.

Bisphosphonates

Alendronate, risedronate, and other bisphosphonates are prescribed to some older patients with ASCVD-related comorbidities including corticosteroid-induced osteoporosis. Calcium taken within 30 to 60 minutes of an oral bisphosphonate dramatically reduces bisphosphonate absorption; the standard instruction is to take bisphosphonates on an empty stomach with plain water only. The American College of Rheumatology's guidance on glucocorticoid-induced osteoporosis reinforces this separation. [10] Inclisiran itself does not interact with bisphosphonates, but prescribers managing complex regimens should review the full medication list.

Statins and Ezetimibe

No pharmacokinetic interaction between calcium and statins or ezetimibe has been identified in the literature. These agents are absorbed by different transporters and metabolized via CYP3A4 or CYP2C8 pathways that calcium does not affect at physiological doses. The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol identifies combination therapy with statins plus inclisiran as appropriate for very high-risk patients who do not reach LDL-C targets on statins alone. [11]

Monitoring Recommendations for Patients Taking Both

LDL-C and Lipid Panel

Inclisiran's effect on LDL-C is typically assessed at the 3-month mark (after the second injection) and then every 6 months aligned with the dosing schedule. The 2022 ACC/AHA guideline recommends a fasting lipid panel 4 to 12 weeks after initiating or adjusting PCSK9-targeting therapy. [11] Calcium supplementation does not interfere with lipid measurement.

Calcium Levels and Renal Function

High-dose supplemental calcium carries a small risk of hypercalcemia and nephrolithiasis, particularly in patients with vitamin D toxicity, primary hyperparathyroidism, or impaired renal function. The NIH ODS notes that the risk of kidney stones is higher in postmenopausal women taking calcium supplementation above 1,000 mg/day. [6] Because inclisiran's renal excretion of metabolite fragments could theoretically concentrate renal load, clinicians prescribing it to patients with CKD stage 3 or above may want to confirm calcium intake does not exceed recommended levels.

Injection Site and Systemic Safety

Inclisiran's most common adverse effects are injection-site reactions (pain, redness, rash) reported in approximately 8.2% of patients in the ORION-10 trial. Systemic adverse effects were similar to placebo in frequency and severity, reinforcing the drug's favorable safety profile in the setting of concomitant medications. [7] Calcium supplements do not worsen injection-site reactions.

What the FDA Label Says About Drug Interactions

The FDA-approved prescribing information for Leqvio (inclisiran) contains no listed interactions with dietary supplements including calcium. The label notes that inclisiran is not a substrate, inhibitor, or inducer of CYP enzymes or major drug transporters. The complete prescribing information is publicly available on FDA's Drugs@FDA database and was last updated following the December 2021 approval. [1]

The absence of a listed interaction is meaningful here because the FDA label for inclisiran explicitly covers the mechanistic reasons no interaction is expected, not merely a gap in data collection.

Practical Guidance: Taking Calcium While on Leqvio

No dose separation between calcium and inclisiran is required. Inclisiran is given by a clinician in a healthcare setting on day 1, day 90, and then every 6 months. Patients are not self-administering it at home, so the everyday timing of calcium supplement ingestion is irrelevant to inclisiran pharmacokinetics.

Patients should, however, take these steps:

• Tell the prescribing clinician the total daily calcium intake, including diet and supplements, at each Leqvio visit.
• Keep supplemental calcium at or below 500 to 600 mg per individual dose, taken with food, to minimize peak serum calcium spikes.
• If also taking levothyroxine, separate levothyroxine from calcium by at least four hours (take levothyroxine first thing in the morning, calcium with lunch or dinner).
• If also taking an oral bisphosphonate, take the bisphosphonate on an empty stomach first, wait at least 30 minutes, then eat and take other medications including calcium.
• Request a fasting lipid panel 3 months after each inclisiran dose to confirm the expected 50% LDL-C reduction is being achieved.

The ACC/AHA 2022 guideline states: "For patients with ASCVD or HeFH who require additional LDL-C lowering beyond maximally tolerated statin therapy, inclisiran provides a twice-yearly dosing option with a favorable safety and tolerability profile." [11] That profile holds regardless of background calcium supplementation.

Summary of Interaction Classification

Classifying the calcium-inclisiran combination using standard interaction frameworks places it in the "no clinically significant interaction" category. The basis for this classification rests on three independent lines of evidence: the subcutaneous route eliminates GI chelation; inclisiran's hepatic metabolism is RNA-nuclease-based, not CYP-based; and ORION trial data across more than 3,000 patients showed no interaction signal with commonly co-administered agents. Calcium's separate, theoretical cardiovascular risk signal warrants discussion for ASCVD patients, but does not modify inclisiran prescribing.